Skip to contentP
Pure Bioscience, Inc.
P
PUREPure Bioscience, Inc. Q2 2019 · 10-Q
Revenue$394.00K$394.00K−4.1% vs Q2 2018 Net Income-$1.30M-$1.30MN/M vs Q2 2018 EPS Diluted-$0.02-$0.02N/M vs Q2 2018 Operating Income-$1,292,000N/M Operating Cash Flow
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Pure Bioscience, Inc. · CIK 1006028 · Engraved from SEC EDGAR
derived
Free Cash Flowderived-$441,000N/M Margins · derivedOperating margin-327.9%+165.5 pt vs Q2 2018
Net margin-328.9%+164.3 pt vs Q2 2018
ended Jan 31, 2019 · filed Mar 6, 2019 · 34 d after period end